📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol (2022)

First Author: Attard G

Attributed to: Evaluating new healthcare technologies in cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(21)02437-5

PubMed Identifier: 34953525

Publication URI: http://europepmc.org/abstract/MED/34953525

Type: Journal Article/Review

Parent Publication: The Lancet

Issue: 10323

ISSN: 0140-6736